Experimental combo for skin cancer shows early promise but study halted

NCT ID NCT03901573

Terminated Disease control Sponsor: NeoImmuneTech Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding an immune-boosting drug (NT-I7) to a standard immunotherapy (atezolizumab) could help people with advanced skin cancers like melanoma, Merkel cell carcinoma, and squamous cell carcinoma. The trial included 31 adults whose cancer had not responded to previous treatments or who had not yet tried similar drugs. The study was stopped early, but researchers looked at safety and tumor shrinkage to guide future research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous neuroendocrine carcinoma melanoma skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS SQUAMOUS CELL CARCINOMA MELANOMA MERKEL CELL CARCINOMA

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Cleveland Clinic

Cleveland, Ohio, 44106, United States
Dana Farber

Boston, Massachusetts, 02215, United States
MGH

Boston, Massachusetts, 02215, United States
Mt Sinai

New York, New York, 10029, United States
Northwestern University

Chicago, Illinois, 60208, United States
Providence Portland Medical Center

Portland, Oregon, 97213, United States
Washington University

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.